[1] LALMANSINGH A S,KARMAKAR S,JIN Y,et al.Multiple modes of chromatin remodeling by Forkhead box proteins[J].Biochim Biophys Acta,2012,1819(7):707-715.
[2] KATOH M,IGARASHI M,FUKUDA H,et al.Cancer genetics and genomics of human FOX family genes[J].Cancer Lett,2013,328(2):198-206.
[3] BERNARDO G M,KERI R A.FOXA1:a transcription factor with parallel functions in development and cancer[J].Biosci Rep,2012,32(2):113-130.
[4] 卢微,刘雅文,程熠.FOXA1的作用机制及作为乳腺癌预后生物标志的研究进展[J].中国老年学杂志,2013,33(3):716-718.
[5] LUPIEN M,EECKHOUTE J,MEYER C A,et al.FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription[J].Cell,2008,132(6):958-970.
[6] 白仲虎,李璐,戴晓峰.转录因子FOXA1在乳腺癌分子分型中的功能研究[J].生物学杂志,2017,34(1):5-10.
[7] 赵小峰,葛保健.FoxA1蛋白的生物信息学分析[J].安徽农业科学,2012,40(24):11953-11956.
[8] 姚磊,刘泰荣,陈华.FoxA家族与恶性肿瘤的发生发展关系研究进展[J/OL].转化医学电子杂志,2018,5(2):45-48.
[9] TSOURLAKIS M C,ELEFTHERIADOU A,STENDER A,et al.FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy[J].Carcinogenesis,2017,38(12):1180-1187.
[10] 冯伟,张红宾,王养民,等.转录因子FOXA1与前列腺癌恶性程度及进展相关性研究[J].中华男科学杂志,2015,21(5):414-419.
[11] JETER C R,LIU B,LU Y,et al.NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis[J].Cell Discov,2016,2:16041.
[12] JIN H J,ZHAO J C,OGDEN I,et al.Androgen receptor-independent function of FoxA1 in prostate cancer metastasis[J].Cancer Res,2013,73(12):3725-3736.
[13] JIN H J,ZHAO J C,WU L,et al.Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program[J].Nat Commun,2014,5:3972.
[14] 侯定坤,王丽丽,李鑫,等.转录因子FOXA1在前列腺癌中的研究进展[J].肿瘤,2018,38(8):806-810.
[15] OBINATA D,TAKAYAMA K,TAKAHASHI S,et al.Crosstalk of the androgen receptor with transcriptional collaborators:potential therapeutic targets for castration-resistant prostate cancer[J].Cancers(Basel),2017,9(3):22.
[16] GERHARDT J,MONTANI M,WILD P,et al.FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer[J].Am J Pathol,2012,180(2):848-861.
[17] JONES D,WADE M,NAKJANG S,et al.FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer[J].Oncotarget,2015,6(30):29782-29794.
[18] DEGRAFF D J,CLARK P E,CATES J M,et al.Loss of the urothelial differentiation marker FOXA1 is associated with high grade,late stage bladder cancer and increased tumor proliferation[J].PLoS One,2012,7(5):e36669.
[19] REDDY O L,CATES J M,GELLERT L L,et al.Loss of FOXA1 drives sexually dimorphic changes in urothelial differentiation and is an independent predictor of poor prognosis in bladder cancer[J].Am J Pathol,2015,185(5):1385-1395.
[20] YEE C H,ZHENG Z,SHUMAN L,et al.Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS[J].Sci Rep,2019,9(1):270.
[21] RAMAN J D,WARRICK J I,CARUSO C,et al.Altered expression of the transcription factor forkhead box a1(FOXA1) is associated with poor prognosis in urothelial carcinoma of the upper urinary tract[J].Urology,2016,94:314.
[22] NEELY B A,WILKINS C E,MARLOW L A,et al.Proteotranscriptomic analysis reveals stage specific changes in the molecular landscape of clear-cell renal cell carcinoma[J].PLoS One,2016,11(4):e0154074.
[23] JIA Z,WAN F,ZHU Y,et al.Forkhead-box series expression network is associated with outcome of clear-cell renal cell carcinoma[J].Oncol Lett,2018,15(6):8669-8680.
[24] TONG Z,MENG X,WANG J,et al.MicroRNA-212 inhibits the proliferation and invasion of human renal cell carcinoma by targeting FOXA1[J].Mol Med Rep,2018,17(1):1361-1367.
[25] 汪峰,张斌斌,郭巍,等.舒尼替尼对转移性肾细胞癌患者临床疗效及生存素、端粒酶表达的影响[J].现代医学,2017,45(4):552-558. |
